277 related articles for article (PubMed ID: 23602401)
21. Structural and energetic effects of A2A adenosine receptor mutations on agonist and antagonist binding.
Keränen H; Gutiérrez-de-Terán H; Åqvist J
PLoS One; 2014; 9(10):e108492. PubMed ID: 25285959
[TBL] [Abstract][Full Text] [Related]
22. Novel approaches for targeting the adenosine A2A receptor.
Yuan G; Gedeon NG; Jankins TC; Jones GB
Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
[TBL] [Abstract][Full Text] [Related]
23. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.
Yang Z; Li X; Ma H; Zheng J; Zhen X; Zhang X
Bioorg Med Chem Lett; 2014 Jan; 24(1):152-5. PubMed ID: 24332624
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.
Shinkre BA; Kumar TS; Gao ZG; Deflorian F; Jacobson KA; Trenkle WC
Bioorg Med Chem Lett; 2010 Oct; 20(19):5690-4. PubMed ID: 20801028
[TBL] [Abstract][Full Text] [Related]
25. A covalent antagonist for the human adenosine A
Yang X; Dong G; Michiels TJM; Lenselink EB; Heitman L; Louvel J; IJzerman AP
Purinergic Signal; 2017 Jun; 13(2):191-201. PubMed ID: 27915383
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
27. Binding mode similarity measures for ranking of docking poses: a case study on the adenosine A2A receptor.
Anighoro A; Bajorath J
J Comput Aided Mol Des; 2016 Jun; 30(6):447-56. PubMed ID: 27334985
[TBL] [Abstract][Full Text] [Related]
28. 3D-QSAR and docking studies on adenosine A2A receptor antagonists by the CoMFA method.
Pourbasheer E; Shokouhi Tabar S; Masand VH; Aalizadeh R; Ganjali MR
SAR QSAR Environ Res; 2015 Jun; 26(6):461-77. PubMed ID: 26055215
[TBL] [Abstract][Full Text] [Related]
29. Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study.
Bortolato A; Tehan BG; Bodnarchuk MS; Essex JW; Mason JS
J Chem Inf Model; 2013 Jul; 53(7):1700-13. PubMed ID: 23725291
[TBL] [Abstract][Full Text] [Related]
30. New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides.
Inamdar GS; Pandya AN; Thakar HM; Sudarsanam V; Kachler S; Sabbadin D; Moro S; Klotz KN; Vasu KK
Eur J Med Chem; 2013 May; 63():924-34. PubMed ID: 23685887
[TBL] [Abstract][Full Text] [Related]
31. 5-Substituted 2-benzylidene-1-tetralone analogues as A
Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ
Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253
[TBL] [Abstract][Full Text] [Related]
32. An efficient route to xanthine based A(2A) adenosine receptor antagonists and functional derivatives.
Labeaume P; Dong M; Sitkovsky M; Jones EV; Thomas R; Sadler S; Kallmerten AE; Jones GB
Org Biomol Chem; 2010 Sep; 8(18):4155-7. PubMed ID: 20652178
[TBL] [Abstract][Full Text] [Related]
33. Computational study of the binding modes of caffeine to the adenosine A2A receptor.
Liu Y; Burger SK; Ayers PW; Vöhringer-Martinez E
J Phys Chem B; 2011 Dec; 115(47):13880-90. PubMed ID: 21970461
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of 2,6-disubstituted-8-amino imidazo[1,2a]pyridines, a promising privileged structure.
Boulahjar R; Rincon Arias A; Bolteau R; Renault N; Coevoet M; Barczyk A; Duroux R; Yous S; Melnyk P; Agouridas L
Bioorg Med Chem; 2018 Jul; 26(12):3296-3307. PubMed ID: 29753566
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the design and optimization of adenosine A2A receptor antagonists.
Vu CB
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):458-68. PubMed ID: 16022182
[TBL] [Abstract][Full Text] [Related]
36. Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A
Masih A; Singh S; Agnihotri AK; Giri S; Shrivastava JK; Pandey N; Bhat HR; Singh UP
Neurosci Lett; 2020 Sep; 735():135222. PubMed ID: 32619652
[TBL] [Abstract][Full Text] [Related]
37. In search of novel ligands using a structure-based approach: a case study on the adenosine A
Lenselink EB; Beuming T; van Veen C; Massink A; Sherman W; van Vlijmen HW; IJzerman AP
J Comput Aided Mol Des; 2016 Oct; 30(10):863-874. PubMed ID: 27629350
[TBL] [Abstract][Full Text] [Related]
38. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
[TBL] [Abstract][Full Text] [Related]
40. 3D pharmacophore based virtual screening of A 2A adenosine receptor antagonists.
Wei J; Qu W; Ye Y; Gao Q
Protein Pept Lett; 2010 Mar; 17(3):332-9. PubMed ID: 20236086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
